Maternal Anemia in Pregnancy: Iron Therapy and Transfusion Decisions

Maternal anemia is one of the most common medical conditions affecting pregnancy. It can arise from iron deficiency, folate deficiency, inherited hemoglobin disorders, inflammation, infection, or blood loss. Iron deficiency remains the leading cause in many populations, particularly where dietary iron intake is low or repeated pregnancies reduce maternal iron reserves.

The clinical challenge is to identify the cause, restore hemoglobin safely, and protect both mother and fetus without treating a laboratory value in isolation. Oral iron is often effective, intravenous iron can be useful when rapid correction is needed, and red-cell transfusion is reserved for specific clinical circumstances.

These decisions belong within the wider field of perinatal medicine presented through the FAOPS 2020 congress, which brought together research and clinical perspectives relevant to maternal and neonatal outcomes. Although the meeting was canceled because of the COVID-19 pandemic, its focus on evidence-based care remains highly relevant to antenatal practice.

Recognizing Anemia During Pregnancy

Pregnancy changes hematologic values through plasma-volume expansion. Hemoglobin and hematocrit may fall because plasma volume increases more rapidly than red-cell mass, a phenomenon often called dilutional or physiologic anemia. This expected change should not be confused with pathologic anemia, particularly when hemoglobin falls below locally accepted pregnancy thresholds or symptoms are present.

Screening is commonly performed at the first prenatal visit and again during the late second or early third trimester. A complete blood count provides the initial picture, including hemoglobin, hematocrit, mean corpuscular volume, and platelet count. Low mean corpuscular volume supports iron deficiency or a hemoglobinopathy, while normal or high cell volume may point toward other causes.

Serum ferritin is generally the most useful test for depleted iron stores, although inflammation can raise ferritin and obscure deficiency. Depending on the presentation, clinicians may also assess transferrin saturation, reticulocyte count, vitamin B12, folate, renal function, hemoglobin electrophoresis, or evidence of infection and bleeding. A low hemoglobin level should trigger diagnostic reasoning rather than automatic transfusion.

Establishing the Cause Before Treatment

Iron deficiency usually reflects increased maternal and fetal requirements, inadequate intake, poor absorption, closely spaced pregnancies, or chronic blood loss. Gastrointestinal disease, previous bariatric surgery, persistent vomiting, and regular use of acid-suppressing medication may reduce iron absorption. A history of heavy menstrual bleeding before conception can reveal that iron stores were already low at the start of pregnancy.

Inherited conditions require particular care. Thalassemia trait, sickle cell disease, and other hemoglobin variants may cause microcytosis or anemia that does not respond to iron. Unnecessary iron exposure can be avoided by confirming deficiency when the laboratory pattern is atypical. Genetic counseling and partner testing may be relevant when a hemoglobinopathy is suspected.

The clinical history should include fatigue, exertional breathlessness, palpitations, dizziness, pica, dietary restrictions, gastrointestinal symptoms, bleeding, medication use, and prior reactions to iron. Severe symptoms, chest pain, syncope, resting dyspnea, hemodynamic instability, or suspected ongoing hemorrhage require urgent assessment. The gestational age, fetal condition, comorbidities, and proximity to delivery all influence the treatment plan.

Choosing Oral or Intravenous Iron

Oral iron is the usual first-line treatment for uncomplicated iron-deficiency anemia. Ferrous sulfate, ferrous fumarate, and ferrous gluconate provide different amounts of elemental iron, so prescriptions should specify the elemental dose rather than relying only on the salt name. The regimen may be given daily or on alternate days, depending on tolerance and local protocols.

Absorption can improve when iron is taken away from calcium-containing foods, tea, coffee, and some antacids. However, gastrointestinal adverse effects frequently limit adherence. Nausea, constipation, abdominal discomfort, and dark stools are common. A practical plan may involve a lower dose, alternate-day administration, a different preparation, dietary counseling, and treatment of constipation rather than abandoning therapy immediately.

A rise in reticulocytes may appear within days, while hemoglobin usually increases over several weeks. The response should be checked after an appropriate interval, often two to four weeks depending on severity. Failure to respond suggests nonadherence, incorrect diagnosis, malabsorption, ongoing blood loss, infection, or an inadequate dose.

Intravenous iron is considered when oral therapy is not tolerated, ineffective, poorly absorbed, or unlikely to correct anemia before delivery. It may also be appropriate in moderate or severe deficiency diagnosed later in pregnancy. The choice of formulation depends on gestational age, local availability, dose requirements, and safety data. Administration should occur where hypersensitivity reactions can be recognized and treated.

Understanding When Transfusion Is Appropriate

Red-cell transfusion is not a routine treatment for uncomplicated iron-deficiency anemia. It supplies an immediate increase in oxygen-carrying capacity but carries risks, including febrile or allergic reactions, transfusion-associated circulatory overload, alloimmunization, and, rarely, serious infectious or immune complications. In pregnancy, alloimmunization may affect the current or a future fetus, making conservative use especially important.

There is no single hemoglobin concentration that determines transfusion for every pregnant patient. A stable person with chronic anemia may tolerate a lower value than someone with acute bleeding, cardiac disease, hypoxia, or significant symptoms. Decisions should include blood pressure, pulse, respiratory status, chest pain, syncope, mental status, active hemorrhage, fetal assessment, and the anticipated timing of delivery.

Transfusion becomes more likely with major obstetric hemorrhage, shock, persistent severe symptoms, or inadequate oxygen delivery despite other measures. It may also be considered when anemia is profound and delivery is imminent, especially if there is insufficient time for iron to work. The decision should be individualized and made with obstetric, anesthesia, hematology, and transfusion medicine input when circumstances are complex.

If transfusion is given for chronic iron deficiency, iron replacement is still needed because red cells do not replenish the underlying iron stores. A restrictive, reassessed approach is commonly used: give the minimum amount needed to stabilize the patient, then review symptoms, hemoglobin, bleeding, and ongoing requirements before additional units.

Balancing Maternal and Fetal Outcomes

Untreated maternal anemia is associated with fatigue, reduced physical capacity, infection risk, impaired recovery, and greater vulnerability to blood loss at delivery. Severe or prolonged anemia has also been linked with preterm birth, fetal growth restriction, low birth weight, and other adverse perinatal outcomes. These associations do not mean that every outcome is caused by anemia; nutritional, socioeconomic, infectious, and obstetric factors often overlap.

Improving maternal iron status can strengthen resilience during labor and reduce the likelihood that moderate blood loss will produce severe symptoms. It also provides an opportunity to address nutrition, antenatal attendance, parasitic disease, gastrointestinal conditions, and access to postpartum follow-up. Treatment should therefore be integrated with broader maternity care rather than handled as an isolated laboratory abnormality.

COVID-19 added complexity to pregnancy care by disrupting travel, appointments, supplies, and hospital capacity. A global COVID-19 review offers useful context for understanding how infection and health-system disruption can affect perinatal outcomes. During infectious outbreaks, clinicians may need to prioritize remote monitoring where safe, streamline laboratory visits, and plan in advance for patients at risk of severe anemia or delivery-related hemorrhage.

Fetal surveillance depends on the severity and timing of maternal illness, along with local protocols. Correcting anemia does not replace assessment of fetal growth, placental function, or other pregnancy complications. Similarly, fetal concerns should not lead automatically to maternal transfusion when the mother is clinically stable; the treatment must address the actual mechanism of risk.

Building a Safe Care Pathway

A reliable approach begins with early screening and clear documentation of the diagnosis. The record should state the likely cause, hemoglobin trend, ferritin or supporting results, prescribed elemental iron dose, adverse effects, follow-up date, and escalation plan. This information supports continuity when care moves between community, hospital, and delivery settings.

Useful recommendations include:

• Screen for anemia early in pregnancy and repeat testing according to local guidance and individual risk.
• Confirm iron deficiency when the blood-count pattern is atypical or a hemoglobinopathy is possible.
• Use oral iron when the patient is stable and there is sufficient time for a response.
• Consider intravenous iron for intolerance, malabsorption, inadequate response, or late-pregnancy correction needs.
• Reserve transfusion for active hemorrhage, instability, severe symptoms, impaired oxygen delivery, or carefully assessed imminent-delivery risk.

Patients should receive practical instructions rather than a prescription alone. They need to know how to take iron, which side effects are expected, when to seek urgent care, and why follow-up testing matters. Dietary advice can support treatment, but food alone is unlikely to correct moderate or severe iron-deficiency anemia quickly.

Preparation for birth is particularly important when anemia persists. The maternity team should review blood-group and antibody information, hemorrhage risk, delivery location, medication history, and the plan for managing postpartum blood loss. After birth, hemoglobin and iron status should be reassessed when symptoms or significant bleeding are present, with continued replacement and follow-up arranged as needed.

Applying Evidence to Individual Care

Maternal anemia management works best when thresholds guide judgment rather than replace it. A patient with mild, asymptomatic iron deficiency may need consistent oral treatment and follow-up, while a patient with the same hemoglobin value but cardiac disease, infection, or imminent delivery may need specialist input. The safest plan is proportional to severity, cause, symptoms, gestational age, and available support.

Clinical teams can improve outcomes by treating iron deficiency early, investigating unexpected results, reducing avoidable transfusion, and planning for hemorrhage before labor begins. Evidence from perinatal medicine continues to refine how maternal blood health affects newborn wellbeing and how services can remain responsive during major disruptions.

Use validated local guidelines, involve the appropriate specialists for severe or unexplained cases, and create a documented plan for iron replacement, laboratory review, and delivery management. Timely recognition and individualized treatment can protect maternal function, preserve transfusion resources, and support a safer start for both mother and baby.